256 related articles for article (PubMed ID: 26997447)
1. Expression of liver fatty acid binding protein in hepatocellular carcinoma.
Cho SJ; Ferrell LD; Gill RM
Hum Pathol; 2016 Apr; 50():135-9. PubMed ID: 26997447
[TBL] [Abstract][Full Text] [Related]
2. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.
Margolskee E; Bao F; de Gonzalez AK; Moreira RK; Lagana S; Sireci AN; Sepulveda AR; Remotti H; Lefkowitch JH; Salomao M
Diagn Pathol; 2016 Mar; 11():27. PubMed ID: 26961851
[TBL] [Abstract][Full Text] [Related]
4. Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA.
Hechtman JF; Abou-Alfa GK; Stadler ZK; Mandelker DL; Roehrl MHA; Zehir A; Vakiani E; Middha S; Klimstra DS; Shia J
Hum Pathol; 2019 Jan; 83():1-6. PubMed ID: 30121369
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular neoplasms with loss of liver fatty acid binding protein: Clinicopathologic features and molecular profiling.
Joseph NM; Blank A; Shain AH; Gill RM; Umetsu SE; Shafizadeh N; Torbenson MS; Kakar S
Hum Pathol; 2022 Apr; 122():60-71. PubMed ID: 35104461
[TBL] [Abstract][Full Text] [Related]
6. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon.
Putra J; Ferrell LD; Gouw ASH; Paradis V; Rishi A; Sempoux C; Balabaud C; Thung SN; Bioulac-Sage P
Mod Pathol; 2020 Apr; 33(4):665-675. PubMed ID: 31570768
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders.
Sempoux C; Paradis V; Komuta M; Wee A; Calderaro J; Balabaud C; Quaglia A; Bioulac-Sage P
J Hepatol; 2015 Nov; 63(5):1173-80. PubMed ID: 26119687
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers.
Bioulac-Sage P; Cubel G; Balabaud C; Zucman-Rossi J
Semin Liver Dis; 2011 Feb; 31(1):91-103. PubMed ID: 21344354
[TBL] [Abstract][Full Text] [Related]
9. Primary hepatic tumors with myxoid change: morphologically unique hepatic adenomas and hepatocellular carcinomas.
Salaria SN; Graham RP; Aishima S; Mounajjed T; Yeh MM; Torbenson MS
Am J Surg Pathol; 2015 Mar; 39(3):318-24. PubMed ID: 25602798
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up.
Shafizadeh N; Genrich G; Ferrell L; Kakar S
Hum Pathol; 2014 May; 45(5):976-83. PubMed ID: 24746201
[TBL] [Abstract][Full Text] [Related]
11. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous occurrence of focal nodular hyperplasia and HNF1A-inactivated hepatocellular adenoma: a collision tumor simulating a composite FNH-HCA.
Shih A; Lauwers GY; Balabaud C; Bioulac-Sage P; Misdraji J
Am J Surg Pathol; 2015 Sep; 39(9):1296-300. PubMed ID: 26274031
[TBL] [Abstract][Full Text] [Related]
13. Unexpected discovery of small HNF1α-inactivated hepatocellular adenoma in pathological specimens from patients resected for liver tumours.
Balabaud C; Laurent C; Le Bail B; Castain C; Possenti L; Frulio N; Chiche L; Blanc JF; Bioulac-Sage P
Liver Int; 2018 Jul; 38(7):1273-1279. PubMed ID: 29265678
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
Bioulac-Sage P; Rebouissou S; Thomas C; Blanc JF; Saric J; Sa Cunha A; Rullier A; Cubel G; Couchy G; Imbeaud S; Balabaud C; Zucman-Rossi J
Hepatology; 2007 Sep; 46(3):740-8. PubMed ID: 17663417
[TBL] [Abstract][Full Text] [Related]
15. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
Nault JC; Couchy G; Balabaud C; Morcrette G; Caruso S; Blanc JF; Bacq Y; Calderaro J; Paradis V; Ramos J; Scoazec JY; Gnemmi V; Sturm N; Guettier C; Fabre M; Savier E; Chiche L; Labrune P; Selves J; Wendum D; Pilati C; Laurent A; De Muret A; Le Bail B; Rebouissou S; Imbeaud S; ; Bioulac-Sage P; Letouzé E; Zucman-Rossi J
Gastroenterology; 2017 Mar; 152(4):880-894.e6. PubMed ID: 27939373
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor.
Kakar S; Grenert JP; Paradis V; Pote N; Jakate S; Ferrell LD
Mod Pathol; 2014 Nov; 27(11):1499-1509. PubMed ID: 24743216
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.
Choi WT; Ramachandran R; Kakar S
Hum Pathol; 2017 May; 63():1-13. PubMed ID: 28087475
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.
Calderaro J; Labrune P; Morcrette G; Rebouissou S; Franco D; Prévot S; Quaglia A; Bedossa P; Libbrecht L; Terracciano L; Smit GP; Bioulac-Sage P; Zucman-Rossi J
J Hepatol; 2013 Feb; 58(2):350-7. PubMed ID: 23046672
[TBL] [Abstract][Full Text] [Related]
19. Immunostains Used to Subtype Hepatic Adenomas Do Not Distinguish Hepatic Adenomas From Hepatocellular Carcinomas.
Liu L; Shah SS; Naini BV; French S; Wu TT; Torbenson MS; Chandan VS
Am J Surg Pathol; 2016 Aug; 40(8):1062-9. PubMed ID: 26927891
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical stains of proliferating cell nuclear antigen, insulin-like growth factor 2 and clusterin help distinguish malignant from benign liver nodular lesions.
Lai JP; Chen ZM; Lok T; Chan OT; Himmelfarb E; Zhai Q; Lin F; Wang HL
J Clin Pathol; 2014 Jun; 67(6):464-9. PubMed ID: 24407433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
